Literature DB >> 23053902

Physicians' perceptions of risks and practices in venous thromboembolism prophylaxis in inflammatory bowel disease.

Justina J Sam1, Charles N Bernstein, Roshan Razik, Reka Thanabalan, Geoffrey C Nguyen.   

Abstract

BACKGROUND: Hospitalized inflammatory bowel disease (IBD) patients are at a higher risk of venous thromboembolism (VTE). AIMS: We aimed to determine perceptions of VTE risks and self-reported practices regarding VTE prophylaxis in hospitalized IBD patients among American gastroenterologists.
METHODS: Gastroenterologists who were members of the American Gastroenterological Association (AGA) and cared for IBD patients in the preceding 12 months were included. A survey assessed physicians' perceptions of VTE risks and their practices regarding VTE prophylaxis among IBD inpatients and other factors that may influence the decision to provide prophylaxis.
RESULTS: A total of 135 eligible gastroenterologists responded to the survey, 77 % of whom practiced in academic settings. Most physicians (84%) reported having had IBD patients develop VTE. Only 67% cared for IBD patients in hospitals that had protocols for VTE prophylaxis, and 45% were aware of any published guidelines for VTE prophylaxis in hospitalized IBD patients. While only 7% believed that any rectal bleeding was a contraindication to VTE chemoprophylaxis in hospitalized IBD patients with flares, 14% never administered prophylaxis to IBD inpatients. A significant number of respondents felt that hospitalized IBD patients who were ambulatory (24%) or in remission (28%) did not require VTE prophylaxis. There was wide variation on recommendations for duration of anticoagulation for a first unprovoked VTE in an IBD patient.
CONCLUSIONS: There is significant variation in reported practices for VTE prophylaxis in IBD patients among gastroenterologists. A more standardized approach to VTE prophylaxis should be implemented to improve health outcomes for IBD inpatients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23053902     DOI: 10.1007/s10620-012-2435-6

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  29 in total

1.  Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial.

Authors:  Alexander T Cohen; Bruce L Davidson; Alexander S Gallus; Michael R Lassen; Martin H Prins; Witold Tomkowski; Alexander G G Turpie; Jan F M Egberts; Anthonie W A Lensing
Journal:  BMJ       Date:  2006-01-26

2.  Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee.

Authors:  Asher Kornbluth; David B Sachar
Journal:  Am J Gastroenterol       Date:  2010-01-12       Impact factor: 10.864

3.  Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements.

Authors:  Alain Bitton; Donald Buie; Robert Enns; Brian G Feagan; Jennifer L Jones; John K Marshall; Scott Whittaker; Anne M Griffiths; Remo Panaccione
Journal:  Am J Gastroenterol       Date:  2011-11-22       Impact factor: 10.864

4.  Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study.

Authors:  Matthew J Grainge; Joe West; Timothy R Card
Journal:  Lancet       Date:  2010-02-08       Impact factor: 79.321

5.  Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.

Authors:  K A Bauer; B I Eriksson; M R Lassen; A G Turpie
Journal:  N Engl J Med       Date:  2001-11-01       Impact factor: 91.245

6.  Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism.

Authors:  Victor F Tapson; Hervé Decousus; Mario Pini; Beng H Chong; James B Froehlich; Manuel Monreal; Alex C Spyropoulos; Geno J Merli; Rainer B Zotz; Jean-François Bergmann; Ricardo Pavanello; Alexander G G Turpie; Mashio Nakamura; Franco Piovella; Ajay K Kakkar; Frederick A Spencer; Gordon Fitzgerald; Frederick A Anderson
Journal:  Chest       Date:  2007-06-15       Impact factor: 9.410

7.  Venous thromboembolism in inflammatory bowel disease.

Authors:  Craig A Solem; Edward V Loftus; William J Tremaine; William J Sandborn
Journal:  Am J Gastroenterol       Date:  2004-01       Impact factor: 10.864

8.  Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism?

Authors:  W Miehsler; W Reinisch; E Valic; W Osterode; W Tillinger; T Feichtenschlager; J Grisar; K Machold; S Scholz; H Vogelsang; G Novacek
Journal:  Gut       Date:  2004-04       Impact factor: 23.059

9.  A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis.

Authors:  Samuel Z Goldhaber; Victor F Tapson
Journal:  Am J Cardiol       Date:  2004-01-15       Impact factor: 2.778

Review 10.  Meta-analysis: The utility and safety of heparin in the treatment of active ulcerative colitis.

Authors:  J Shen; Z H Ran; J L Tong; S D Xiao
Journal:  Aliment Pharmacol Ther       Date:  2007-09-01       Impact factor: 8.171

View more
  21 in total

Review 1.  Quality of care delivered to hospitalized inflammatory bowel disease patients.

Authors:  Adam V Weizman; Geoffrey C Nguyen
Journal:  World J Gastroenterol       Date:  2013-10-14       Impact factor: 5.742

2.  Levels of TAFI, TFPI and ADAMTS-13 in inflammatory bowel disease.

Authors:  Bilgehan Yüzbaşıoğlu; Müge Ustaoğlu; Şule Yüzbaşıoğlu; Ulaş Emre Akbulut; Kamil Özdil
Journal:  Turk J Gastroenterol       Date:  2019-12       Impact factor: 1.852

3.  IBD: postoperative VTE prophylaxis in IBD.

Authors:  Geoffrey C Nguyen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-11-27       Impact factor: 46.802

4.  Mind the gap: venous thromboembolism prophylaxis in patients hospitalized with inflammatory bowel disease.

Authors:  John I Allen
Journal:  Dig Dis Sci       Date:  2013-01       Impact factor: 3.199

5.  Oral administration of ginger-derived nanolipids loaded with siRNA as a novel approach for efficient siRNA drug delivery to treat ulcerative colitis.

Authors:  Mingzhen Zhang; Xiaoyu Wang; Moon Kwon Han; James F Collins; Didier Merlin
Journal:  Nanomedicine (Lond)       Date:  2017-06-30       Impact factor: 5.307

Review 6.  Defining quality indicators for best-practice management of inflammatory bowel disease in Canada.

Authors:  Geoffrey C Nguyen; Shane M Devlin; Waqqas Afif; Brian Bressler; Steven E Gruchy; Gilaad G Kaplan; Liliana Oliveira; Sophie Plamondon; Cynthia H Seow; Chadwick Williams; Karen Wong; Brian M Yan; Jennifer Jones
Journal:  Can J Gastroenterol Hepatol       Date:  2014-05

7.  The use of pharmacological prophylaxis against venous thromboembolism in hospitalised patients with severe active ulcerative colitis.

Authors:  J L Pleet; B P Vaughn; J A Morris; A C Moss; A S Cheifetz
Journal:  Aliment Pharmacol Ther       Date:  2014-03-10       Impact factor: 8.171

8.  Minor Hematochezia Decreases Use of Venous Thromboembolism Prophylaxis in Patients with Inflammatory Bowel Disease.

Authors:  Adam S Faye; Kenneth W Hung; Kimberly Cheng; John W Blackett; Anna Sophia Mckenney; Adam R Pont; Jianhua Li; Garrett Lawlor; Benjamin Lebwohl; Daniel E Freedberg
Journal:  Inflamm Bowel Dis       Date:  2020-08-20       Impact factor: 5.325

9.  Guideline recommendations for treatment of patients with inflammatory bowel diseases are not implemented in clinical practice-results of a non-representative survey.

Authors:  Lea I Kredel; Oliver Schneidereit; Jörg C Hoffmann; Britta Siegmund; Jan C Preiß
Journal:  Int J Colorectal Dis       Date:  2018-12-07       Impact factor: 2.571

10.  Venous thromboembolism in patients with inflammatory bowel diseases: a case-control study of risk factors.

Authors:  Elizabeth A Scoville; Gauree G Konijeti; Deanna D Nguyen; Jenny Sauk; Vijay Yajnik; Ashwin N Ananthakrishnan
Journal:  Inflamm Bowel Dis       Date:  2014-04       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.